{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:32:19Z","timestamp":1793241139494,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Step therapy (\u201cfail-first\u201d) policies require patients to initiate treatment with a payer-preferred regimen, often selected for cost, before coverage is granted for the oncologist-recommended therapy. In medical oncology, where biologic heterogeneity, biomarker-directed therapy, and time-sensitive sequencing determine outcomes, step edits can function as an avoidable barrier to evidence-based care. We performed a narrative review of peer-reviewed literature (2010-2025) and relevant US regulatory and policy documents to summarize the clinical, economic, and equity implications of step therapy as applied to systemic anticancer treatments. Evidence from cancer-specific and cross-cutting utilization management research suggests that coverage restrictions can delay initiation or continuation of therapy and increase treatment discontinuation. We synthesize mechanisms of harm (time-to-treatment delays, forced non-guideline-concordant sequencing, and toxicity exposure), describe contemporary case examples across therapeutic areas, and propose actionable policy remedies. Oncology-specific safeguards, including transparent clinical criteria, rapid exceptions and appeals, continuity-of-care protections, and provider performance-based exemptions (\u201cgold-carding\u201d), are essential to balance payer oversight with the imperatives of precision oncology.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag398","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T10:53:10Z","timestamp":1791802390000},"source":"Crossref","is-referenced-by-count":0,"title":["The perils and consequences of payer step editing (\u201cStep Therapy\u201d) in US medical oncology: evidence, case examples, and policy remedies"],"prefix":"10.1093","volume":"31","author":[{"given":"Lucio N","family":"Gordan","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Florida Cancer Specialists & Research Institute , Gainesville, FL 32605,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0863-7547","authenticated-orcid":false,"given":"Kristen","family":"Boykin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Operations, Florida Cancer Specialists & Research Institute , Tampa, FL 33609,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reff","sequence":"additional","affiliation":[{"name":"National Community Oncology Dispensing Association , Cazenovia, NY 13035,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chadwick","sequence":"additional","affiliation":[{"name":"Executive Leadership, Florida Cancer Specialists & Research Institute , Tampa, FL 33609,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana","family":"Mehring","sequence":"additional","affiliation":[{"name":"Payer Strategy and Revenue Cycle Management, Florida Cancer Specialists & Research Institute , Tampa, FL 33609,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Cox","sequence":"additional","affiliation":[{"name":"Trade Relations, Florida Cancer Specialists & Research Institute , Tampa, FL 33609,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wenk","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Florida Cancer Specialists & Research Institute , Trinity, FL 34655,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Fink","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Florida Cancer Specialists & Research Institute , Tampa, FL 33613,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Eaves","sequence":"additional","affiliation":[{"name":"Executive Leadership, Florida Cancer Specialists & Research Institute , Tampa, FL 33609,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ciarrocchi","sequence":"additional","affiliation":[{"name":"Executive Leadership, Florida Cancer Specialists & Research Institute , Tampa, FL 33609,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2026102822022714400_oyag398-B1","doi-asserted-by":"publisher","first-page":"m4087","DOI":"10.1136\/bmj.m4087","article-title":"Mortality due to cancer treatment delay: systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"},{"key":"2026102822022714400_oyag398-B2","author":"Centers for Medicare & Medicaid Services","year":"2018"},{"key":"2026102822022714400_oyag398-B3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","article-title":"Limits to personalized cancer medicine","volume":"375","author":"Tannock","year":"2016","journal-title":"N Engl J Med"},{"key":"2026102822022714400_oyag398-B4","doi-asserted-by":"publisher","first-page":"e2338182","DOI":"10.1001\/jamanetworkopen.2023.38182","article-title":"The patient experience of prior authorization for cancer care","volume":"6","author":"Chino","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026102822022714400_oyag398-B5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1200\/JCO.23.01693","article-title":"Prior authorization and association with delayed or discontinued prescription fills","volume":"42","author":"Kyle","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026102822022714400_oyag398-B6","author":"American Cancer Society Cancer Action Network; Avalere Health","year":"2024"},{"key":"2026102822022714400_oyag398-B7","author":"Biniek","year":"2026"},{"key":"2026102822022714400_oyag398-B8","author":"American Cancer Society Cancer Action Network; Avalere Health","year":"2024"},{"key":"2026102822022714400_oyag398-B9","author":"Office of Inspector General, U.S. Department of Health and Human Services","year":"2022"},{"key":"2026102822022714400_oyag398-B10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1200\/OP.2024.20.10_suppl.18","article-title":"Increased biosimilar options in oncology and impact on administrative burden caused by drug switches: Implications of step therapy","volume":"20","author":"Poole","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026102822022714400_oyag398-B11","author":"Community Oncology Alliance","year":"2026"},{"key":"2026102822022714400_oyag398-B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/CA.2007.0011","article-title":"Association of insurance with cancer care utilization and outcomes","volume":"58","author":"Ward","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"2026102822022714400_oyag398-B13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1470-2045(08)70032-9","article-title":"Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis","volume":"9","author":"Halpern","year":"2008","journal-title":"Lancet Oncol"},{"key":"2026102822022714400_oyag398-B14","author":"National Comprehensive Cancer Network"},{"key":"2026102822022714400_oyag398-B15","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102822022714400_oyag398-B16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102822022714400_oyag398-B17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102822022714400_oyag398-B18","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026102822022714400_oyag398-B19","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026102822022714400_oyag398-B20","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026102822022714400_oyag398-B21","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"2026102822022714400_oyag398-B22","author":"Centers for Medicare & Medicaid Services","year":"2024"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag398\/71869316\/oyag398.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag398\/71869316\/oyag398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag398\/71869316\/oyag398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:02:33Z","timestamp":1793239353000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag398\/8910355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag398","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,7]]},"article-number":"oyag398"}}